Allarity Therapeutics Inc. (ALLR)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Bioventus (BVS) have performed compared to their sector so far this year.
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Drops By 20.7%
Allarity Therapeutics, Inc. (NASDAQ: ALLR - Get Free Report) was the recipient of a large decline in short interest during the month of February. As of February 27th, there was short interest totaling 227,623 shares, a decline of 20.7% from the February 12th total of 287,071 shares. Currently, 1.4% of the company's shares are short sold.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities prior to May 17, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.
Allarity Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $1.09 | $1.43 | $0.34 | 31.19% |
Allarity Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| EW Edward Woo Ascendiant Capital | 19,779.99 | $30,955.69 | $28,285.39 | -$2,670.3 | -8.63% |
Allarity Therapeutics Inc. (ALLR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Allarity Therapeutics Inc. ever had a stock split?
Allarity Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Thomas H. Jensen CEO | NASDAQ (CM) Exchange | 016744500 CUSIP |
| US Country | 6 Employees | - Last Dividend | 11 Sep 2024 Last Split | 21 Dec 2021 IPO Date |
Overview
Allarity Therapeutics, Inc. is a forward-thinking clinical-stage biopharmaceutical corporation committed to the development of novel oncology therapeutics. The company sets itself apart by leveraging drug-specific companion diagnostics, produced through its proprietary technology, the Drug Response Predictor (DRP®) technology. This innovative approach aims to tailor treatments to individual patients, potentially increasing the efficacy and safety of oncology therapies. Founded in 2004, Allarity Therapeutics has rooted its headquarters in Boston, Massachusetts, placing itself in one of the globe's most vibrant biotech hubs. Through its collaborative efforts, including a significant partnership with Detsamma Investments Pty. Ltd. for the development of Deflexifol aimed at treating solid tumors, Allarity Therapeutics is actively contributing to the oncology field by advancing drug candidates through clinical trials.
Products and Services
The products and clinical candidates of Allarity Therapeutics, Inc. comprise a diverse portfolio aimed at addressing various cancer types through distinct mechanisms of action:
- Stenoparib - A poly-ADP-ribose polymerase (PARP) inhibitor, currently undergoing Phase 2 clinical trials for treating ovarian cancer. PARP inhibitors are a class of pharmacological inhibitors that play a significant role in cell repair processes, making Stenoparib a promising candidate for treating cancers that have defective DNA repair mechanisms.
- Dovitinib - This drug acts as a pan-tyrosine kinase inhibitor and is being evaluated for its effectiveness in renal cell carcinoma treatment. Tyrosine kinases are enzymes involved in the activation of various proteins by signal transduction cascades, and their inhibition can thwart cancer cell growth and proliferation.
- IXEMPRA (ixabepilone) - As a selective microtubule inhibitor, IXEMPRA is currently in phase 2 trials for metastatic breast cancer. Microtubule inhibitors disrupt the microtubule dynamics that are crucial for cell division, thereby inhibiting the growth of cancer cells.
- LiPlaCis - A liposomal formulation of cisplatin, LiPlaCis offers a Phase 2 clinical trial focusing on patients with metastatic breast cancer. Liposomal formulations encapsulate drugs in vesicles to improve delivery and reduce toxicity, with cisplatin being a potent chemotherapy drug that causes DNA damage, leading to cell death in cancer cells.
- 2X-111 - Another liposomal formulation, but of doxorubicin for Phase 2 clinical trials targeting metastatic breast cancer and glioblastoma multiforme. Doxorubicin is a chemotherapy drug known for its broad spectrum of activity against various cancers, and its formulation into liposomes aims to enhance tumor targeting and reduce adverse effects.
Together, these initiatives underscore Allarity Therapeutics, Inc.’s commitment to advancing oncology treatment protocols, with each product and service showcasing its unique approach to cancer therapy.
